BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Angelopoulou E, Paudel YN, Julian T, Shaikh MF, Piperi C. Pivotal Role of Fyn Kinase in Parkinson's Disease and Levodopa-Induced Dyskinesia: a Novel Therapeutic Target? Mol Neurobiol 2021;58:1372-91. [PMID: 33175322 DOI: 10.1007/s12035-020-02201-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Dong X, Li Y, Li Q, Li W, Wu G. Identification of immune signatures in Parkinson’s disease based on co-expression networks. Front Genet 2023;14. [DOI: 10.3389/fgene.2023.1090382] [Reference Citation Analysis]
2 Angelopoulou E, Pyrgelis ES, Piperi C. Emerging Potential of the Phosphodiesterase (PDE) Inhibitor Ibudilast for Neurodegenerative Diseases: An Update on Preclinical and Clinical Evidence. Molecules 2022;27. [PMID: 36500540 DOI: 10.3390/molecules27238448] [Reference Citation Analysis]
3 Soni D, Kumar P. GSK-3β-mediated regulation of Nrf2/HO-1 signaling as a new therapeutic approach in the treatment of movement disorders. Pharmacol Rep 2022. [PMID: 35882765 DOI: 10.1007/s43440-022-00390-z] [Reference Citation Analysis]
4 Höllerhage M, Stepath M, Kohl M, Pfeiffer K, Chua OW, Duan L, Hopfner F, Eisenacher M, Marcus K, Höglinger GU. Transcriptome and Proteome Analysis in LUHMES Cells Overexpressing Alpha-Synuclein. Front Neurol 2022;13:787059. [DOI: 10.3389/fneur.2022.787059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Alam M, Ahmed S, Elasbali AM, Adnan M, Alam S, Hassan MI, Pasupuleti VR. Therapeutic Implications of Caffeic Acid in Cancer and Neurological Diseases. Front Oncol 2022;12:860508. [PMID: 35359383 DOI: 10.3389/fonc.2022.860508] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
6 Muhammad F, Liu Y, Zhou Y, Yang H, Li H. Antioxidative role of Traditional Chinese Medicine in Parkinson's disease. J Ethnopharmacol 2022;285:114821. [PMID: 34838943 DOI: 10.1016/j.jep.2021.114821] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
7 Oláh J, Szénási T, Lehotzky A, Norris V, Ovádi J. Challenges in Discovering Drugs That Target the Protein-Protein Interactions of Disordered Proteins. Int J Mol Sci 2022;23:1550. [PMID: 35163473 DOI: 10.3390/ijms23031550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kovač V, Čurin Šerbec V. Prion Protein: The Molecule of Many Forms and Faces. Int J Mol Sci 2022;23:1232. [PMID: 35163156 DOI: 10.3390/ijms23031232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Garrido A, Santamaría E, Fernández-Irigoyen J, Soto M, Simonet C, Fernández M, Obiang D, Tolosa E, Martí MJ, Padmanabhan S, Malagelada C, Ezquerra M, Fernández-Santiago R. Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease. Mov Disord 2022. [PMID: 35049090 DOI: 10.1002/mds.28927] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Jo S, Park KW, Hwang YS, Lee SH, Ryu HS, Chung SJ. Microarray Genotyping Identifies New Loci Associated with Dementia in Parkinson's Disease. Genes (Basel) 2021;12:1975. [PMID: 34946922 DOI: 10.3390/genes12121975] [Reference Citation Analysis]
11 de Pins B, Mendes T, Giralt A, Girault JA. The Non-receptor Tyrosine Kinase Pyk2 in Brain Function and Neurological and Psychiatric Diseases. Front Synaptic Neurosci 2021;13:749001. [PMID: 34690733 DOI: 10.3389/fnsyn.2021.749001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
12 Demuro S, Di Martino RMC, Ortega JA, Cavalli A. GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways. Int J Mol Sci 2021;22:9098. [PMID: 34445804 DOI: 10.3390/ijms22169098] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
13 Guglietti B, Carr L, Ellul B, Mustafa S, Corrigan F, Collins-praino LE. Fyn kinase inhibition using AZD0530 improves recognition memory and reduces depressive-like behaviour in an experimental model of Parkinson’s disease.. [DOI: 10.1101/2021.06.16.448746] [Reference Citation Analysis]
14 Bordone MP, Damianich A, Bernardi MA, Eidelman T, Sanz-Blasco S, Gershanik OS, Avale ME, Ferrario JE. Fyn knockdown prevents levodopa-induced dyskinesia in a mouse model of Parkinson's disease. eNeuro 2021:ENEURO. [PMID: 34099487 DOI: 10.1523/ENEURO.0559-20.2021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]